Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 71 Neoplasms 28 Neoplasm Metastasis 15 Colorectal Neoplasms 9 Multiple Myeloma 6 Thyroid Neoplasms 5 Skin Neoplasms 5 Lymphoma, Non-Hodgkin 5 Carcinoma, Non-Small-Cell Lung 5 Thyroid Cancer, Papillary 4 Leukemia, Hairy Cell 4 Hematologic Neoplasms 4 Sarcoma 3 Pancreatic Neoplasms 3 Glioma 3 Breast Neoplasms 3 Wilms Tumor 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Recurrence 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoma 2

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × Vemurafenib × Clear all

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡